Recordati Industria Chimica e Farmaceutica S.p.A. (VIE:REC)
Austria
· Delayed Price · Currency is EUR 48.96
-0.30 (-0.61%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Italy Revenue | 339.11M | 336.26M |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue | 2.14B | 2.01B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography 2
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Europe Revenue | 1.65B |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue | 156.01M |
Log In |
Log In |
Log In | Upgrade
|
| America Revenue | 477.46M |
Log In |
Log In |
Log In | Upgrade
|
| Africa Revenue | 58.03M |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Specialty & Primary Care Revenue | 1.53B | 1.51B |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Revenue | 950.29M | 833.86M |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Cardiovascular Revenue | 399.15M | 385.21M |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Uro-Oncology Revenue | 404.56M | 399.94M |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Revenue | 226.95M | 217.50M |
Log In |
Log In |
Log In | Upgrade
|
| Cough and Cold Revenue | 129.52M | 137.28M |
Log In |
Log In |
Log In | Upgrade
|
| Other Treatment Areas Revenue | 308.65M | 309.31M |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Chemicals Revenue | 60.62M | 58.47M |
Log In |
Log In |
Log In | Upgrade
|
| Hema-Oncology Revenue | 336.71M | 253.23M |
Log In |
Log In |
Log In | Upgrade
|
| Endocrinology Revenue | 347.03M | 321.69M |
Log In |
Log In |
Log In | Upgrade
|
| Metabolic and Other Areas Revenue | 266.55M | 258.94M |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 3
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Pharmaceutical Chemicals Revenue | 60.62M | 58.47M |
Log In |
Log In |
Log In | Upgrade
|
| Zanidip Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Zanipress Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Urorec Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Livazo Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Seloken/Logimax Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Eligard Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Corporate Products Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Drugs for Rare Diseases Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| OTC Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Local Product Portfolios Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
EBITDA
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Specialty & Primary Care EBITDA | 516.45M | 524.44M |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases EBITDA | 392.73M | 341.33M |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Specialty & Primary Care Operating Income | 404.03M | 426.73M |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Operating Income | 227.32M | 212.13M |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Specialty & Primary Care Like-For-Like Growth | 5.70% |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Like-For-Like Growth | 15.70% |
Log In |
Log In |
Log In | Upgrade
|
| Total Like-For-Like Growth | 9.20% |
Log In |
Log In |
Log In | Upgrade
|